A phase I clinical trial of a first-in-class FASN inhibitor, TVB-2640, in patients with solid tumors (ClinicalTrials.gov identifier NCT02223247) shows preliminary anti-tumor activity [21]. The gene discussed is FASN; the disease is neoplasm.